MK-0954E Study in Participants With Hypertension (MK-0954E-357)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 327 participants.
Also called NCT01302691
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 327 participants
- Sponsor
- Registry
-
NCT01302691
-
- Main results
- Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01302691. Randomized; double masking; primary purpose treatment. Start 2011-01-01 (actual); primary completion 2012-04-01 (actual). Results posted on 2017-01-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MK-0954E Study in Participants With Hypertension (MK-0954E-357)
- Condition
- Hypertension
- Intervention (Drug)
- losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)
- Intervention (Drug)
- Losartan potassium
- Intervention (Drug)
- Amlodipine besylate
- Intervention (Drug)
- Placebo to MK-0954E
- Intervention (Drug)
- Placebo to losartan potassium
- Intervention (Drug)
- Placebo to amlodipine besylate
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01302691- Content hash
4a1fa0107e9182c7d37817502fbcebc6a9f06603611717c741c91c1cdbd0fe17